Maternal Cardiometabolic Indicators Prior to Pregnancy and Their Association with Subsequent Hypertensive Disorders During Gestation

Overview

This study investigates the association between pregestational cardiometabolic disturbances and the risk of hypertensive disorders of pregnancy (HDP) in nulliparous women. Findings suggest that certain biomarkers related to lipid and glucose metabolism may be linked to increased HDP risk, highlighting the importance of early identification and intervention.

Background

Hypertensive disorders of pregnancy (HDP) are prevalent and significant contributors to maternal and neonatal morbidity and mortality. The increasing incidence of HDP is concerning, particularly given its association with long-term cardiovascular disease risk. Identifying preconception risk factors is crucial for developing effective prevention strategies.

Data Highlights

No specific numerical data or trial data were provided in the source material.

Key Findings

Clinical Implications

Healthcare providers should consider assessing cardiometabolic health indicators in women prior to conception to identify those at risk for HDP. Early intervention through lifestyle modifications may reduce the incidence of HDP and improve maternal and neonatal outcomes.

Conclusion

The study underscores the need for a stronger evidence base regarding preconception cardiometabolic health and its impact on hypertensive disorders during pregnancy. Early identification and intervention may play a critical role in mitigating risks associated with HDP.

References

1. European Journal of Preventive Cardiology, 2025 -- Urgent Recommendations for Lifestyle Modifications During Pregnancy to Lower Offspring Cardiovascular Risk
2. The Journal of Clinical Endocrinology & Metabolism, 2025 -- Linking Pregnancy Complications to Long-term Cardiometabolic Health Outcomes in Mothers: Insights from the MIREC Cohort Study
3. The Journal of Clinical Endocrinology & Metabolism, 2025 -- Cortisol Patterns Throughout Pregnancy: Current Knowledge Gaps and Challenges
4. Clinical Guidance for the Integration of the Findings of the Chronic Hypertension and Pregnancy (CHAP) Study | ACOG, 2022
5. The effect of maternal pre-pregnancy body mass index on hypertensive disorders of pregnancy (HDP): a systematic review and dose-response meta-analysis of cohort studies involving 50 million pregnancies, 2025
6. Archives of Gynecology and Obstetrics — Advanced fetal cardiac monitoring in gestational diabetes mellitus: HbA1c remains the relevant predictor of perinatal outcome under optimal metabolic control
7. Clinical Guidance for the Integration of the Findings of the Chronic Hypertension and Pregnancy (CHAP) Study | ACOG
8. The effect of maternal pre-pregnancy body mass index on hypertensive disorders of pregnancy (HDP): a systematic review and dose-response meta-analysis of cohort studies involving 50 million pregnancies - PMC
9. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement | Nephrology | JAMA | JAMA Network